We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




RDW Blood Test Can Predict Mortality and Re-Admission Among Elderly, Hospitalized Patients

By LabMedica International staff writers
Posted on 25 May 2022

Red cell distribution width (RDW), an index for variation of red blood cell size, has been proposed as a potential marker for poorer outcomes in several aging-related diseases and conditions. More...

The biological mechanisms linking greater variability of RBC size and adverse health-related outcomes are not known, however emerging evidence supports the use of RDW as a marker for biologic aging, disease vulnerability, oxidative stress and chronic inflammation. Now, new research has found that higher RDW is associated with increased rates of in-hospital mortality and hospital re-admission among older (>60) patients.

In a retrospective analysis, investigators at Sutter’s California Pacific Medical Center (CPMC, Davis, CA, USA) studied 94,617 patients aged >60 who were hospitalized between January 2013 to December 2017 at Sutter Health. A total of 167,292 admissions were included. The RDW was measured during hospital admission and categorized with 1% intervals. The primary outcome was the rate of in-hospital mortality; secondary outcomes included 30-day re-admission rate and length of hospital stay.

Results showed the overall in-hospital mortality rate was 6.3%. As the RDW value increased, the rate of in-hospital mortality increased from 2.7% for the lowest RDW category to 12.2% in the highest category (p-trend <0.001). The overall 30-day re-admission rate after discharge was 12.5% and the rate of 30-day readmission also increased with increasing RDW categories (7.4% in the lowest group vs. 15.8% in the highest group, p-trend <0.001). Patients with the highest RDW values at admission stayed 1.5–2.0 times longer in the hospital than patients with lower RDW values who were admitted for the same causes.

“Greater variability of red blood cell size is significantly associated with worse prognosis in hospitalized elderly patients, indicating higher mortality, greater risk of early re-admission and longer hospital stay days. Risk stratification strategies for hospitalized elderly should include RDW value,” said Steve Cummings, M.D., lead author of the study, director of the SFCC and a principal investigator at CPMC.

“Predicting the risk of mortality and re-admission are critical for in-patient care. An accurate risk classification strategy for patients can also improve outcomes in clinical practice,” added Warren Browner, M.D., co-author of the study and CEO of CPMC. “However, there are no strong predictors of mortality or early re-admission that can be applied across multiple aging-related diseases. These findings provide the potential of RDW value, one of the most common laboratory tests that are performed for most hospitalized patients, as a biomarker for poorer prognosis or vulnerability in hospitalized elderly patients.”

Related Links:
CPMC 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.